Filing Details
- Accession Number:
- 0001179110-12-013430
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-08-28 19:01:33
- Reporting Period:
- 2012-08-24
- Filing Date:
- 2012-08-28
- Accepted Time:
- 2012-08-28 19:01:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1080014 | Theravance Inc | THRX | Pharmaceutical Preparations (2834) | 943265960 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1318005 | W Michael Aguiar | Theravance, Inc. 901 Gateway Boulevard South San Francisco CA 94080 | Sr Vp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-08-24 | 4,121 | $17.91 | 157,168 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-08-24 | 4,121 | $28.01 | 153,047 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-08-27 | 17,700 | $27.24 | 135,347 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-08-27 | 2,861 | $27.86 | 132,486 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2012-08-24 | 4,121 | $0.00 | 4,121 | $17.91 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
170,879 | 2015-03-06 | No | 4 | M | Direct |
Footnotes
- Dispositions made pursuant to a plan intended to comply with rule 10b5-1(c).
- This transaction was executed in multiple trades at prices ranging from $28.00 to $28.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $26.70 to $27.69. The price reported above reflects the weighted average sale price.
- This transaction was executed in multiple trades at prices ranging from $27.71 to $27.98. The price reported above reflects the weighted average sale price.
- Immediately exercisable.